Abstract
Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central nervous system (CNS) in which macrophages play a pivotal and multifaceted role. These highly plastic immune cells are key effectors in the immunopathology of MS, contributing to both inflammatory-driven demyelination and subsequent tissue repair. Historically, macrophage function was viewed through the binary lens of pro-inflammatory M1 and anti-inflammatory M2 polarization. However, recent research reveals a far more complex spectrum of activation states within the dynamic microenvironment of MS lesions. Understanding the intricate signals and molecular pathways that govern macrophage polarization in the CNS represents a critical frontier for therapeutic innovation. Interventions aimed at rebalancing macrophage phenotypes have yielded encouraging results in preclinical models, and some therapeutic agents are now advancing into clinical trials. Future investigations are focused on the diverse functions of macrophages in MS pathogenesis, including their involvement in oxidative stress, antigen presentation, and myelin debris clearance. A particularly innovative approach involves harnessing macrophages as cellular vehicles for targeted drug delivery across the blood-brain barrier, offering a potential solution to one of the most significant challenges in CNS therapeutics. The primary challenge now lies in the safe and effective clinical translation of these macrophage-centered therapies. Successfully navigating this transition from bench to bedside holds the potential to deliver transformative treatments that can halt disease progression and restore neurological function for individuals living with this debilitating disease.